Extracorporeal immunoadsorption for the specific removal of lipoprotein (a) (Lp(a) apheresis): preliminary clinical data
| Autor: | Olga I. Afanasieva, Sergei N. Pokrovsky, Anatoly A. Lyakishev, I. Adamova, Andrei V. Sussekov, Kukharchuk Vv |
|---|---|
| Rok vydání: | 1994 |
| Předmět: |
Adult
Male medicine.medical_specialty Time Factors Urology Coronary Disease Biochemistry Extracorporeal Hyperlipoproteinemia Type II Coronary artery disease chemistry.chemical_compound Blood plasma medicine Humans Immunoadsorption Molecular Biology Immunosorbent Techniques Apolipoproteins B biology Chemistry Cholesterol Organic Chemistry Blood Proteins Cell Biology Lipoprotein(a) Middle Aged medicine.disease Apheresis Immunology Blood Component Removal biology.protein lipids (amino acids peptides and proteins) Lipoprotein |
| Zdroj: | Chemistry and Physics of Lipids. :323-330 |
| ISSN: | 0009-3084 |
| DOI: | 10.1016/0009-3084(94)90153-8 |
| Popis: | The extracorporeal procedure for the specific removal of lipoprotein (a) (Lp(a)) from human plasma — Lp(a) apheresis — was applied to the treatment of three patients with coronary artery disease documented by angiography. Their initial lipid levels were as follows: total cholesterol, 210–230 mg/dl; low-density lipoprotein (LDL) cholesterol, 140–160 mg/dl; Lp(a), 90–120 mg/dl. The patients underwent a total of 168 procedures without significant side effects. Lp(a) apheresis reduced the Lp(a) level by removing up to 88% of Lp(a). Other plasma compounds, including LDL and plasminogen, remained practically unchanged. Lp(a) apheresis appears to be a unique, effective and specific method for lowering the Lp(a) level. Additional trials are needed to evaluate the clinical effect of this treatment. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|